KRAS and non-small cell lung carcinoma: In the TRIBUTE trial, which compared first‐line paclitaxel/carboplatin plus erlotinib or placebo in advanced NSCLC patients, the objective response rate (ORR), time to progression (TTP) and OS did not differ according to KRAS mutation status.38